"Markov Chains" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A stochastic process such that the conditional probability distribution for a state at any future instant, given the present state, is unaffected by any additional knowledge of the past history of the system.
| Descriptor ID |
D008390
|
| MeSH Number(s) |
E05.318.740.600.500 E05.318.740.996.500 G17.830.500 N05.715.360.750.625.500 N05.715.360.750.770.500 N06.850.520.830.600.500 N06.850.520.830.996.500
|
| Concept/Terms |
Markov Chains- Markov Chains
- Chains, Markov
- Markov Process
- Markov Processes
- Process, Markov
- Processes, Markov
- Markov Chain
- Chain, Markov
|
Below are MeSH descriptors whose meaning is more general than "Markov Chains".
Below are MeSH descriptors whose meaning is more specific than "Markov Chains".
This graph shows the total number of publications written about "Markov Chains" by people in this website by year, and whether "Markov Chains" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 7 | 7 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 8 | 9 |
| 2014 | 0 | 5 | 5 |
| 2015 | 3 | 4 | 7 |
| 2016 | 2 | 5 | 7 |
| 2017 | 2 | 5 | 7 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 3 | 4 |
| 2020 | 0 | 4 | 4 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 2 | 4 |
| 2025 | 0 | 6 | 6 |
| 2026 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Markov Chains" by people in Profiles.
-
Cost-Effectiveness of the I'm Ready HIV Self-Testing Programme Among High-Risk Populations in Canada. J Int AIDS Soc. 2026 Apr; 29(4):e70097.
-
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness Analysis. JCO Glob Oncol. 2026 Jan; 12:e2400435.
-
Cost-effectiveness analysis of surgical repair versus observation of complex abdominal aortic aneurysms in elderly patients. J Vasc Surg. 2026 03; 83(3):699-709.e5.
-
Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective. J Manag Care Spec Pharm. 2025 Sep; 31(9):900-908.
-
Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis. Atherosclerosis. 2025 Oct; 409:120447.
-
Inferring chromosome segregation error stage and crossover in trisomic disorders with application to Down syndrome. Nat Commun. 2025 Jul 09; 16(1):6316.
-
Projected Survival Benefit of Fenestrated Endovascular Aneurysm Repair versus Observation for Complex Abdominal Aortic Aneurysms in Patients with Limited Life Expectancy. Ann Vasc Surg. 2025 Nov; 120:345-353.
-
Using a Markov Model and Real-World Evidence to Identify the Most Cost-Effective Cholesterol Treatment Escalation Threshold for the Secondary Prevention of Cardiovascular Disease. Appl Health Econ Health Policy. 2025 09; 23(5):869-883.
-
A health economic analysis of noninjectable epinephrine compared with intramuscular epinephrine. Ann Allergy Asthma Immunol. 2025 05; 134(5):587-593.e1.
-
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.